FDA approves Bayer’s HER2-mutated lung cancer drug

The FDA on Wednesday granted accelerated approval to Bayer’s targeted lung cancer drug for certain HER2 mutations, setting up competition with a Boehringer Ingelheim drug that was recently approved for a ...